CAMBRIDGE, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corp., a clinical-stage biotechnology company harnessing the power of regulatory RNA to restore healthy gene expression, today ...
Urea cycle disorders (UCDs) constitute a group of rare, inherited metabolic conditions arising from deficiencies in key enzymes of the urea cycle – the biochemical pathway responsible for converting ...
CAMP4 Therapeutics reports promising results for CMP-SYNGAP-01 and CMP-CPS-001 in treating genetic disorders, with favorable safety data. CAMP4 Therapeutics announced promising results from its ...
A physician scientist is making strides in understanding the molecular origins of fatty liver disease, a leading cause of liver failure in the United States. An Indiana University School of Medicine ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback